132 related articles for article (PubMed ID: 8020872)
1. Structure activity relationship of phosphoramidon derivatives for in vivo endothelin-converting-enzyme inhibition.
Bigaud M; Hauss B; Schalk C; Jauch MF; D'Orchymont H
Fundam Clin Pharmacol; 1994; 8(2):155-61. PubMed ID: 8020872
[TBL] [Abstract][Full Text] [Related]
2. Rhamnose moiety of phosphoramidon is not required for in vivo inhibition of endothelin converting enzyme.
Pollock DM; Shiosaki K; Sullivan GM; Opgenorth TJ
Biochem Biophys Res Commun; 1992 Jul; 186(2):1146-50. PubMed ID: 1497648
[TBL] [Abstract][Full Text] [Related]
3. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats.
McMahon EG; Palomo MA; Brown MA; Bertenshaw SR; Carter JS
Am J Hypertens; 1993 Aug; 6(8):667-73. PubMed ID: 8217029
[TBL] [Abstract][Full Text] [Related]
4. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.
Kukkola PJ; Savage P; Sakane Y; Berry JC; Bilci NA; Ghai RD; Jeng AY
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S65-8. PubMed ID: 8587470
[TBL] [Abstract][Full Text] [Related]
5. Phosphoramidon blocks the pressor activity of big endothelin[1-39] and lowers blood pressure in spontaneously hypertensive rats.
McMahon EG; Palomo MA; Moore WM
J Cardiovasc Pharmacol; 1991; 17 Suppl 7():S29-33. PubMed ID: 1725358
[TBL] [Abstract][Full Text] [Related]
6. Role of endothelin-converting enzyme in the systemic hemodynamics and regional circulatory effects of proendothelin-1 (1-38) and diaspirin cross-linked hemoglobin in rats.
Gulati A; Singh R; Chung SM; Sen AP
J Lab Clin Med; 1995 Dec; 126(6):559-70. PubMed ID: 7490515
[TBL] [Abstract][Full Text] [Related]
7. Effect of endothelin-converting enzyme inhibitors on big endothelin-1 induced contraction in isolated rat basilar artery.
Zimmermann M; Jung CS; Vatter H; Raabe A; Seifert V
Acta Neurochir (Wien); 2002 Nov; 144(11):1213-9. PubMed ID: 12434178
[TBL] [Abstract][Full Text] [Related]
8. Effects of metalloprotease inhibitors on the conversion of proendothelin-1 to endothelin-1.
Trapani AJ; Balwierczak JL; Lappe RW; Stanton JL; Graybill SC; Hopkins MF; Savage P; Sperbeck DM; Jeng AY
Biochem Mol Biol Int; 1993 Dec; 31(5):861-7. PubMed ID: 8136704
[TBL] [Abstract][Full Text] [Related]
9. Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1.
Murphy LJ; Corder R; Mallet AI; Turner AJ
Br J Pharmacol; 1994 Sep; 113(1):137-42. PubMed ID: 7529108
[TBL] [Abstract][Full Text] [Related]
10. Disparate effects of phosphoramidon on blood pressure in SHR and DOCA-salt hypertensive rats.
Vemulapalli S; Watkins RW; Brown A; Cook J; Bernardino V; Chiu PJ
Life Sci; 1993; 53(10):783-93. PubMed ID: 8355566
[TBL] [Abstract][Full Text] [Related]
11. Diuretic-natriuretic actions and pressor effects of big-endothelin (1-39) in phosphoramidon-treated rats.
Hoffman A; Haramati A; Dalal I; Shuranyi E; Winaver J
Proc Soc Exp Biol Med; 1994 Feb; 205(2):168-73. PubMed ID: 8108467
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11.
Trapani AJ; De Lombaert S; Kuzmich S; Jeng AY
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S69-71. PubMed ID: 8587471
[TBL] [Abstract][Full Text] [Related]
13. Big endothelin-3-induced hypertension and its inhibition by phosphoramidon in anaesthetized rats.
Matsumura Y; Fujita K; Takaoka M; Morimoto S
Eur J Pharmacol; 1993 Jan; 230(1):89-93. PubMed ID: 8094056
[TBL] [Abstract][Full Text] [Related]
14. Effects of phosphoramidon on endothelin-1 and big endothelin-1 production in human aortic endothelial cells.
Matsumura Y; Tsukahara Y; Kojima T; Murata S; Murakami A; Takada K; Takaoka M; Morimoto S
Biol Pharm Bull; 1995 Mar; 18(3):401-6. PubMed ID: 7550091
[TBL] [Abstract][Full Text] [Related]
15. Effects of metalloprotease inhibitors on smooth muscle endothelin-converting enzyme activity.
Balwierczak JL; Kukkola PJ; Savage P; Jeng AY
Biochem Pharmacol; 1995 Jan; 49(3):291-6. PubMed ID: 7857315
[TBL] [Abstract][Full Text] [Related]
16. Phosphoramidon inhibits the conversion of big ET-1 into ET-1 in the pithed rat and in isolated perfused rat kidneys.
Verbeuren TJ; Mennecier P; Merceron D; Simonet S; de Nanteuil G; Vincent M; Laubie M
J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S81-4. PubMed ID: 7510006
[TBL] [Abstract][Full Text] [Related]
17. Detection by bioassay and specific enzyme-linked immunosorbent assay of phosphoramidon-inhibitable endothelin-converting activity in brain and endothelium.
Warner TD; Budzik GP; Mitchell JA; Huang ZJ; Murad F
J Cardiovasc Pharmacol; 1992; 20 Suppl 12():S19-21. PubMed ID: 1282965
[TBL] [Abstract][Full Text] [Related]
18. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
Trapani AJ; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Jeng AY
Life Sci; 2000; 67(9):1025-33. PubMed ID: 10954036
[TBL] [Abstract][Full Text] [Related]
19. Molecular pharmacology of endothelin converting enzymes.
Turner AJ; Murphy LJ
Biochem Pharmacol; 1996 Jan; 51(2):91-102. PubMed ID: 8615890
[TBL] [Abstract][Full Text] [Related]
20. Contraction to big endothelin-1, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi.
Yap EY; Battistini B; McKay KO
Br J Pharmacol; 2000 Jan; 129(1):170-6. PubMed ID: 10694217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
